证券代码：603858 证券简称：步长制药 公告编号：2025-116

Group 1 - The company approved a capital reduction for its subsidiary, Shandong Buchang Medicine Diagnostic Technology Co., Ltd., reducing its registered capital from 58.823 million to 11.868 million yuan [2][3] - The capital reduction agreement was signed recently, and the reduction does not involve returning any capital to the shareholders, with the consideration being zero [2][3] - The capital structure of the subsidiary will change after the reduction, but the specific details are not provided in the summary [3] Group 2 - The purpose of the capital reduction is to optimize resource allocation and improve capital efficiency, aligning with the company's operational needs [9] - After the capital reduction, the subsidiary will remain a controlled subsidiary of the company, and there will be no significant impact on the company's consolidated financial statements or current profits and losses [9]